Voyager Therapeutics (VYGR) Tops Q3 EPS by 29c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts VYGR Hot Sheet
Join SI Premium – FREE
Voyager Therapeutics (NASDAQ: VYGR) reported Q3 EPS of ($0.16), $0.29 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $24.63 million versus the consensus estimate of $11.7 million.
For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- BillionToOne, Inc. (BLLN) Tops Q3 EPS by 23c; Offers Guidance
- Innoviva (INVA) Misses Q3 EPS by 156c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
